Efficacy of cabozantinib and sunitinib for the treatment of intermediate/poor risk renal cell carcinoma based upon UK real-world data
Our results showed no significant difference in either OS or PFS between treatments. Cabozantinib trended towards improved PFS and reduced OS. Decision-making for tyrosine kinase inhibitor monotherapy should consider later-line treatment options. This analysis is of particular relevance as sunitinib is now off-patent meaning that the cost of a course of treatment has considerably reduced.
Authors
- Ricky Frazer (ORCID: https://orcid.org/0009-0002-0509-1506)
- Amit K. Bahl (ORCID: https://orcid.org/0000-0002-8525-0310)
- John McGrane (ORCID: https://orcid.org/0000-0001-9371-3250)
- G. J. Meléndez‐Torres (ORCID: https://orcid.org/0000-0002-9823-4790)
- Amarnath Challapalli (ORCID: https://orcid.org/0000-0002-3683-9583)
- Dawn Lee (ORCID: https://orcid.org/0000-0003-4027-8456)
Institutions
- University of Exeter (GB)
- Royal Cornwall Hospital (GB)
- University Hospitals Bristol NHS Foundation Trust (GB)
- Velindre Cancer Centre (GB)
- University Hospitals Bristol and Weston NHS Foundation Trust (GB)
Publication Details
- Journal
- ESMO Real World Data and Digital Oncology
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1016/j.esmorw.2024.100087
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute for Health and Care Research
- Health Technology Assessment Programme